Peptides 101: What They Are and How to Tell What Is Prescribable

Peptides are short chains of amino acids, typically ranging from two to about fifty amino acids in length, linked by peptide bonds. They are distinct from proteins primarily by size: most scientists draw the line at around 50 amino acids, though definitions vary. Peptides occur naturally throughout the human body and play critical roles as hormones, neurotransmitters, and signaling molecules that regulate processes from metabolism to immune function.

In medicine, peptides have become increasingly important therapeutic agents. Insulin, a 51-amino-acid peptide hormone, has been used to treat diabetes since the 1920s and remains one of the most widely prescribed drugs in the world. More recently, GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed the treatment of type 2 diabetes and obesity. Other well-known peptide drugs include oxytocin, vasopressin, calcitonin, and gonadotropin-releasing hormone (GnRH) analogs used in oncology and reproductive medicine.

The therapeutic potential of peptides is vast because they can be designed to interact with specific biological targets with high selectivity and potency while often producing fewer off-target effects than small-molecule drugs. However, their regulatory status varies enormously: some are rigorously tested and FDA-approved, while others are sold without any regulatory oversight. Understanding these distinctions is essential for patients, clinicians, and anyone evaluating peptide products.

The FDA approves peptide drugs through the same New Drug Application (NDA) or Biologics License Application (BLA) process used for all pharmaceutical products. A manufacturer must conduct preclinical studies, followed by phased clinical trials (Phase I for safety, Phase II for efficacy, Phase III for large-scale confirmation) before submitting an application with comprehensive data on the drug's safety, efficacy, manufacturing quality, and proposed labeling. The entire process typically takes 10 to 15 years and costs hundreds of millions of dollars.

Once approved, a peptide drug appears in the Drugs@FDA database, which is the public-facing record of all FDA-approved drug products. The drug's official prescribing information (package insert) is published on DailyMed, maintained by the National Library of Medicine. The FDA Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) lists approved drugs and their generic equivalents, providing information on patent and exclusivity status.

It is worth noting that some peptide therapies are regulated as biologics rather than drugs, depending on their molecular characteristics and manufacturing process. Since the Biologics Price Competition and Innovation Act (BPCIA), many peptide products have transitioned from drug to biologic classification, which affects the approval pathway and how generic (biosimilar) versions can be introduced to market.

FDA-approved peptides are drugs or biologics that have completed the full regulatory review process. They are manufactured under strict Good Manufacturing Practice (GMP) standards, carry FDA-approved labeling with dosing information, and are available through licensed pharmacies with a valid prescription. Examples include semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and insulin products. These represent the highest standard of safety and quality assurance.

Gray-zone compounded peptides occupy a legally complex middle ground. Under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, licensed pharmacies and registered outsourcing facilities may compound certain peptide preparations under specific conditions, such as drug shortages or when a patient has a medical need that cannot be met by a commercially available product. These compounded products are not FDA-approved, but they are legally manufactured when all regulatory requirements are met. The gray zone arises because enforcement varies and the legal boundaries are actively contested, particularly around products like compounded semaglutide.

Research-only peptides are products manufactured and sold exclusively for laboratory or scientific research purposes. They have no FDA approval, no regulatory oversight for human safety, and no legal pathway for clinical use. Despite this, a large online market exists where research peptides are marketed in ways that suggest human use, often with dosing information and customer testimonials. Purchasing and self-administering research peptides carries significant risks including unknown purity, incorrect dosing, contamination, and no recourse if something goes wrong.

The phrase "for research use only" or "not for human consumption" on a peptide product is a legal disclaimer, not a safety assurance. Companies that sell research peptides use this language to position their products outside FDA jurisdiction, arguing that they are selling chemical reagents rather than drugs. In practice, many of these companies know their products are being purchased for self-administration, and some actively market them with dosing guides, injection instructions, and before-and-after testimonials.

The FDA has taken enforcement action against numerous companies selling unapproved peptide products. Warning letters have been issued to firms selling products labeled as BPC-157, AOD-9604, ipamorelin, and others, citing violations of the Federal Food, Drug, and Cosmetic Act. These letters make clear that products intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease are drugs under federal law, regardless of what the label says.

Products manufactured without FDA oversight do not undergo testing for purity, potency, sterility, or endotoxin levels. Independent analyses of research peptides have found significant variability in actual peptide content, the presence of degradation products, and in some cases bacterial contamination. Patients who self-administer these products are assuming risks that are difficult to quantify because the products themselves are uncharacterized.

Verifying the regulatory status of any peptide is straightforward using free, publicly available FDA and NIH tools. Start with the Drugs@FDA database at accessdata.fda.gov/scripts/cder/daf/ and search for the peptide by its generic name (e.g., "semaglutide"). If the peptide has an approved NDA or BLA, it will appear with details about the approved products, manufacturers, and approval dates. If nothing appears, the peptide is not FDA-approved as a drug.

Next, check DailyMed at dailymed.nlm.nih.gov, which hosts the official labeling for all marketed drugs. This will confirm whether the peptide has FDA-approved prescribing information. You can also consult ClinicalTrials.gov to see if the peptide is being studied in active clinical trials, which indicates scientific interest but does not imply approval. Finally, a search on PubMed (pubmed.ncbi.nlm.nih.gov) can reveal peer-reviewed studies on the peptide's safety and efficacy.

If a peptide does not appear in Drugs@FDA and has no NDA or BLA, it is not an FDA-approved drug. If it appears only in research literature or early-phase clinical trials, it is still investigational. If it is sold online with "research use only" labeling, it has no regulatory standing for human use. Our detailed verification guide walks through each step with screenshots and examples.